Alvotech (Nasdaq:ALVO) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ALVO 주식 개요

알보텍은 자회사를 통해 전 세계 환자를 위한 바이오시밀러 의약품을 개발 및 제조합니다.

ALVO 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	5/6
과거 실적	0/6
재무 상태	1/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 80.1% 에서 거래

수익은 매년 98.09% 증가할 것으로 예상됩니다.

위험 분석

마이너스 주주 지분

지난 1년 동안 주주가 희석되었습니다.

Alvotech 경쟁사

Denali Therapeutics

NasdaqGS:DNLI

US$3.3b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.7b

Arcellx

NasdaqGS:ACLX

US$3.0b

Amicus Therapeutics

NasdaqGM:FOLD

US$2.9b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Alvotech
과거 주가
현재 주가	US$12.36
52주 최고치	US$18.00
52주 최저치	US$8.03
베타	-0.046
11개월 변경	-10.95%
3개월 변경 사항	8.42%
1년 변경 사항	46.62%
33년 변화	25.48%
5년 변화	n/a
IPO 이후 변화	26.77%

최근 뉴스 및 업데이트

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Recent updates

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

Alvotech starts pharmacokinetic study for its biosimilar to Amgen's bone disease drugs

Jul 20

Icelandic biosimilars developer Alvotech initiated with a hold rating by Deutsche Bank

Jul 01

주주 수익률

	ALVO	US Biotechs	US 마켓
7D	-7.2%	-1.6%	-0.06%
1Y	46.6%	10.4%	20.5%

수익률 대 산업: ALVO 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ALVO 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ALVO's price volatile compared to industry and market?
ALVO volatility
ALVO Average Weekly Movement	4.8%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ALVO 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ALVO 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2013	999	Robert Wessman	www.alvotech.com

알보텍은 자회사를 통해 전 세계 환자를 위한 바이오시밀러 의약품을 개발 및 제조하고 있습니다. 암뿐만 아니라 자가면역, 안과, 뼈 질환 치료 분야에서 바이오시밀러 제품을 제공합니다. 회사의 주요 프로그램은 류마티스 관절염, 건선성 관절염, 크론병, 궤양성 대장염, 판상 건선 및 기타 적응증을 포함한 다양한 염증성 질환을 치료하는 휴미라의 고농도 제형 바이오시밀러인 AVT02와 건선성 관절염, 크론병, 궤양성 대장염, 판상 건선 및 기타 적응증을 포함하는 다양한 염증성 질환을 치료하는 스텔라의 바이오시밀러인 AVT04가 있다; 연령 관련 황반변성, 황반부종, 당뇨병성 망막증 등 다양한 질환을 치료하는 아일리아의 바이오시밀러인 AVT06, 특정 유형의 암 환자의 골절, 척수 압박, 방사선 또는 뼈 수술의 필요성을 예방하고 골 손실을 방지하고 골량을 증가시키기 위해 전임상 단계에 있는 엑스게바 및 프롤리아의 바이오시밀러인 AVT03이 있습니다.

Alvotech 기본 사항 요약

Alvotech 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ALVO 기본 통계
시가총액	US$3.40b
수익(TTM)	-US$494.28m
수익(TTM)	US$114.39m

30.2x

P/S 비율

-7.0x

P/E 비율

ALVO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ALVO 손익 계산서(TTM)
수익	US$114.39m
수익 비용	US$141.72m
총 이익	-US$27.32m
기타 비용	US$466.96m
수익	-US$494.28m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

Aug 28, 2024

주당 순이익(EPS)	-1.77
총 마진	-23.89%
순이익 마진	-432.09%
부채/자본 비율	-148.5%

ALVO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ALVO 주식 개요

보상

위험 분석

Alvotech 경쟁사

NasdaqGS:DNLI

US$3.3b

NasdaqGS:RARE

US$3.7b

NasdaqGS:ACLX

US$3.0b

NasdaqGM:FOLD

US$2.9b

가격 내역 및 성능

최근 뉴스 및 업데이트

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Recent updates

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

Alvotech to Report Q1, 2023 Results on May 18, 2023

Consensus revenue estimates increase by 10%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment